Summary:
An open-label, randomized two treatment, multi-site multiple dose, steady state, three-way, reference-replicated crossover, pharmacokinetic study to determine the in-vivo bioequivalence between Asenapine 10 mg sublingual tablet and SAPHRIS (Asenapine) 10 mg sublingual tablet 3 week study.
Participants will receive a stable twice daily dose of Asenapine Maleate EQ 10mg base sublingual tablets for at least 3 months prior to randomization. Subjects otherwise healthy
.Subjects will be housed for up to 3 days and two (2) nights
Qualified Participants May Receive:
Assistance with transportation and Stipend for their time